Re: Saccharomyces Cerevisiae (incl S Boulardii) May Cause Fungemia in Critically

[Guest guest]

I don't know. I find this study somewhat preliminary or perhaps if

this is just the abstract, more answers can be found in reading

the entire study.

It's always been my understanding (and I'm NOT a doctor) that

this type of systemic fungemia or even bacterial infection could

occur only if there is a so-called " leaky-gut " issue -- or if the

patient is receiving medicine or nutrition through a tube (which

could contaminated and spreading an infection). Note the

" central venous catheter " that was involved in some of these

cases...

" S. boulardii should certainly be contraindicated for patients of

fragile health, as well as for patients with a central venous

catheter in place, " the editorialists conclude. "

Just my two cents!

d.

p.s. I've never heard about " probiotic resistance " either. Learn

something new every day........

> Don't forget Barb , even good gut probiotic bugs are invaders ,

we develop

> antibodies against them . without the recognition protein coat

....all

> probiotics are destined to become ineffective as resistance

[antibodies]

> develops

> [infections] Re: Saccharomyces

Cerevisiae (incl S

> Boulardii) May Cause Fungemia in Critically Ill Patients

>

>

> Hey. That's why I'm here- to learn.

> This is interesting.

> I guess the key is balance.

>

> I knew that the gut bugs had to be balanced, and that an over

growth

> of even what's normally called a " good gut bug " could cause

problems,

>

> BUT I didn't know you could over dose a probiotic - and cause

an

> overgrowth...on the contrary- I thought probiotics were quite

> ineffective.. i.e. not very many CFUs in products and poor

viability

> in the gut.

>

> Barb

>

>

>

> > > > In France, Ultralevure (made of S. Boulardii) is

routinely

> > > prescribed by doctors to prevent abx related diarrhea.

> > > >

> > > > Nelly

> > > >

> > > > (...)

> > > > "

> > > > " This review confirms that the most important risk

factor

> for

> > S.

> > > cerevisiae fungemia is the use of probiotics, " write Dr.

Raoul

> > > Herbrecht and Dr. Yasmine Nivoix from Hopital de

Hautepierre,

> > > Strasbourg, France in a related editorial.

> > > >

> > > > " This raises the question of the risk-benefit ratio of

these

> > agents

> > > in critically ill or immunocompromised patients who are

> likely to

> > > develop an infection after exposure to high amounts of a

> pathogen

> > > with a low virulence. "

> > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > To Print: Click your browser's PRINT button.

> > > > NOTE: To view the article with Web

enhancements, go

> to:

> > > > http://www.medscape.com/viewarticle/505940

> > > >

> > > >

> > > > ------------------------------------------------------------

> ----

> > ----

> > > ------

> > > >

> > > > Saccharomyces Cerevisiae May Cause Fungemia

in

> Critically

> > Ill

> > > Patients

> > > >

> > > >

> > > >

> > > > NEW YORK (Reuters Health) Jun 03 - Treatment

with the

> > > probiotic Saccharomyces cerevisiae may lead to

fungemia in

> > > immunosuppressed or critically ill patients,

investigators in

> > Madrid

> > > report.

> > > >

> > > > S. cerevisiae is commonly used as a probiotic for

the

> > > treatment of antibiotic-related diarrhea, Dr.

Munoz

> from

> > > Hospital General Universitario " Gregorio Maranon, " and

> colleagues

> > > explain.

> > > >

> > > > They identified three patients with S. cerevisiae

> > fungemia in

> > > an intensive care unit and reviewed the literature to

identify

> > > similar cases. All three patients had been treated for

> > Clostridium

> > > difficile-associated diarrhea with Ultralevura, a

formulation

> of

> > S.

> > > boulardii (a strain of S. cerevisiae), the authors report,

and

> > all

> > > three died of various causes.

> > > >

> > > > The strains isolated from the three patients were

> > identical

> > > to the strains from the probiotic formulation, according

to

> the

> > > results in the June 1st issue of Clinical Infectious

> Diseases. No

> > > further cases were detected after the discontinuation of

> > Ultralevura

> > > in the intensive care unit.

> > > >

> > > > Review of the literature identified 57 additional

> cases

> > of S.

> > > cerevisiae fungemia, the researchers note, and at least

31

> > patients

> > > were receiving probiotics or potentially exposed to other

> > patients

> > > who were receiving probiotics.

> > > >

> > > > The mortality rate among the reported cases of S.

> > cerevisiae

> > > fungemia was 28%.

> > > >

> > > > " The extent of this review indicates that S.

> cerevisiae

> > > should be considered as a well-established cause of

> nosocomially

> > > acquired yeast infection, particularly in patients

receiving

> > > prophylaxis or treatment with the probiotic Ultralevura,

which

> > should

> > > be considered a risk factor for nosocomial bloodstream

> infection

> > in

> > > patients with predisposing underlying conditions, " the

authors

> > > conclude.

> > > >

> > > > " Therapy for S. cerevisiae fungemia should rely on

the

> > > withdrawal of the probiotic preparation, if it was being

> given,

> > > administration of an antifungal agent, and, as with other

> types

> > of

> > > fungemia, withdrawal of central venous catheters, " the

> > researchers

> > > advise.

> > > >

> > > > " Until more data are available, " the investigators

> > > suggest, " the antifungal agent of choice seems to be

> amphotericin

> > B. "

> > > >

> > > > " This review confirms that the most important risk

> factor

> > for

> > > S. cerevisiae fungemia is the use of probiotics, " write

Dr.

> Raoul

> > > Herbrecht and Dr. Yasmine Nivoix from Hopital de

Hautepierre,

> > > Strasbourg, France in a related editorial.

> > > >

> > > > " This raises the question of the risk-benefit ratio of

> > these

> > > agents in critically ill or immunocompromised patients

who are

> > likely

> > > to develop an infection after exposure to high amounts

of a

> > pathogen

> > > with a low virulence. "

> > > >

> > > > " S. boulardii should certainly be contraindicated for

> > > patients of fragile health, as well as for patients with a

> > central

> > > venous catheter in place, " the editorialists

> conclude. " Whether

> > this

> > > probiotic still has a place in less severe situations

needs

> to be

> > > reassessed. "

> > > >

> > > > Clin Infect Dis 2005;40:1625-1637.

> > > >

> > > >

> > > > ------------------------------------------------------------

> ----

> > ----

> > > ------

> > >

> > >

> > >

> > >

> > >

> > >

> > >

[Guest guest]

>

> > Have you tried enzymes and long chain fatty acids??

> >

> > My IgA titer for Candida was 2.5 (normal is < 0.8)

> > after

> > lyme therapy. IgA and IgM were not out of range, so

> > my DOc and I

> > figured it was still contained in my mucosal

> > membranes.

> >

> > It took 8 months- but Candex and Lauric acid

> > (Lauricidin or Coconut

> > oil) brought me back to normal.

> >

> > Barb

> >

> >

[Guest guest]

Thanks Jerry. I will do a search for the coconut oil

too.

Marie

--- geraldod <geraldod@...> wrote:

>

> >

> > > Have you tried enzymes and long chain fatty

> acids??

> > >

> > > My IgA titer for Candida was 2.5 (normal is <

> 0.8)

> > > after

> > > lyme therapy. IgA and IgM were not out of

> range, so

> > > my DOc and I

> > > figured it was still contained in my mucosal

> > > membranes.

> > >

> > > It took 8 months- but Candex and Lauric acid

> > > (Lauricidin or Coconut

> > > oil) brought me back to normal.

> > >

> > > Barb

> > >

> > >

>

>

>

>

____________________________________________________

Sports

Rekindle the Rivalries. Sign up for Fantasy Football

http://football.fantasysports.